CLINICAL TRIALS PROFILE FOR CETACORT

All Clinical Trials for Cetacort

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002798 ↗	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	Children's Cancer Group	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Clinical Trial Conditions for Cetacort

Condition Name

Condition Name for Cetacort
Intervention	Trials
T-cell Childhood Acute Lymphoblastic Leukemia	3
Recurrent Childhood Acute Lymphoblastic Leukemia	3
B Acute Lymphoblastic Leukemia	2

Condition MeSH

Condition MeSH for Cetacort
Intervention	Trials
Leukemia	9
Leukemia, Lymphoid	7
Precursor Cell Lymphoblastic Leukemia-Lymphoma	7

Clinical Trial Locations for Cetacort

Trials by Country

Trials by Country for Cetacort
Location	Trials
United States	334
Canada	44
Australia	12
Puerto Rico	5
New Zealand	5

Trials by US State

Trials by US State for Cetacort
Location	Trials
California	10
New York	10
Minnesota	9
Massachusetts	9
Illinois	9

Clinical Trial Progress for Cetacort

Clinical Trial Phase

Clinical Trial Phase for Cetacort
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Cetacort
Clinical Trial Phase	Trials
Completed	6
Active, not recruiting	5
Terminated	2

Clinical Trial Sponsors for Cetacort

Sponsor Name

Sponsor Name for Cetacort
Sponsor	Trials
National Cancer Institute (NCI)	14
Children's Oncology Group	7
Hospital for Special Surgery, New York	1

Sponsor Type

Sponsor Type for Cetacort
Sponsor	Trials
NIH	14
Other	14
Industry	1

Last updated: April 28, 2026

Cetacort: What Is the Current Clinical and Commercial Trajectory?

Is there enough verifiable basis to report Cetacort clinical trials and market projections?

No. The request targets a specific drug name (“Cetacort”) but no supplied context identifies the active ingredient, formulation, indication set, market geography, or the exact product (brand, salt, strength, manufacturer). Without that mapping, any clinical-trial update, competitive landscape, pricing/launch assumptions, or patent/market projection would require unverifiable leaps.

Because the question is explicitly for “Clinical trials update, market analysis and projection,” producing a complete and accurate response is impossible under the available information constraints.

What can be stated from the provided inputs?

• No clinical trial registry identifiers (e.g., NCT numbers), trial phases, enrollment status, topline dates, or publication links were provided.
• No indication (e.g., ophthalmic, dermatologic, respiratory, inflammatory) was provided.
• No geography (US/EU/UK/JP/ROW) was provided.
• No commercial inputs (incumbents, pricing, payer coverage, channel structure, or expected launch timing) were provided.

Given these gaps, any “update” and any “projection” would be based on assumptions rather than deliverable business-grade facts.

---

Key Takeaways

• A complete and accurate clinical-trials update and market projection for “Cetacort” cannot be produced from the information provided.
• The drug must be unambiguously identified by active ingredient and exact product mapping before trial and market work can be executed.

---

FAQs

1) What information is required to update Cetacort clinical trials?

A verifiable mapping from “Cetacort” to the active ingredient and exact product, plus an indication, so trials can be identified by registry entries and publications.

2) Why can’t you project market size for Cetacort without more detail?

Market forecasts depend on indication, route of administration, dosing regimen, geography, comparator set, and expected market access timeline.

3) Does “Cetacort” always refer to the same product across countries?

Brand names can differ by geography and can also map to different active ingredients, strengths, or combinations, so name-only reporting can misattribute data.

4) Can clinical trial updates be generated without trial IDs?

A credible update requires registry or publication traceability (for phase, status, and dates).

5) Can competitive landscape analysis proceed without indication mapping?

No. Competitors, endpoints, and payer dynamics are indication-specific.

---

References

[1] No sources were provided in the prompt.